Radius, 3M Drug Delivery Systems Announce Exclusive Agreement for Development, Commercialization of Transdermal Delivery of

  Radius, 3M Drug Delivery Systems Announce Exclusive Agreement for
  Development, Commercialization of Transdermal Delivery of BA058 for
  Osteoporosis

Business Wire

CAMBRIDGE, Mass. -- December 20, 2012

Radius Health, Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to
announce an exclusive partnership agreement for development and
commercialization of BA058-transdermal (TD). BA058 is a novel, synthetic
proprietary peptide analog of human parathyroid hormone related protein or
“hPTHrP,” a bone building anabolic compound with the potential to treat
patients with osteoporosis at high risk of fracture. This agreement updates
the general development agreement announced in May 2011 by the two companies
for BA058-TD.

The BA058-TD patch applicator prototype. (Photo: Business Wire)

The BA058-TD patch applicator prototype. (Photo: Business Wire)

BA058-transdermal (TD) is being studied in a Phase 2 clinical trial in healthy
postmenopausal women with osteoporosis at 10 clinical centers. BA058-TD is a
short-wear time patch based on 3M's patented Microstructured Transdermal
System technology. The transdermal patch is expected to combine ease of use,
convenience and self-administration attributes of a patch with the bone
building efficacy of the BA058 compound.

“We are excited that 3M Drug Delivery Systems, which has long demonstrated a
commitment to quality, safety and innovation, is partnering with us to bring a
novel approach of drug delivery to the underserved osteoporosis patient
population,” said Michael Wyzga, Radius president and chief executive officer.
“Our study data for BA058-TD showed that a five-minute wear time of the patch
delivers peak drug levels consistent with subcutaneous injection and we hope
to see increased patient compliance with 3M’s innovative technology.”

3M Drug Delivery Systems has partnered with pharmaceutical companies worldwide
for more than 50 years, providing customized solutions to drug delivery.

“We are pleased to be part of Radius’ mission of advancing therapeutics for
healthy aging with its deep expertise in osteoporosis,” said Ingrid Blair,
MTS/TDD business vice president of 3M Drug Delivery Systems. “With this
exclusive agreement, 3M and Radius demonstrate our commitment to this
innovative therapeutic treatment and this unique drug delivery mechanism. We
believe this new drug potentially will improve the health of patients with
severe osteoporosis and that 3M’s microneedle patch technology may improve
medication compliance among patients.”

BA058 is also being studied as a daily subcutaneous injection (BA058-SC) in a
Phase 3 study with 2,400 patients for fracture prevention in women with
postmenopausal osteoporosis at high risk of fracture. Phase 2 human testing of
the injectable BA058-SC showed that BA058 significantly increased bone mineral
density (BMD) at the lumbar spine and femoral neck (a common osteoporotic
fracture site located in the hip joint) after six months of therapy.

About Radius

Radius is a biopharmaceutical company focused on developing and
commercializing advanced therapeutics to support healthy aging. We aspire to
improve the quality of life in older adults by treating age-related
conditions.

Radius is committed to the development of advanced therapeutics for the large
and underserved osteoporosis market. The Company’s lead product candidate,
BA058-SC, is in development to reduce the risk of complications associated
with osteoporosis, such as fracture. In Phase 2 trials, BA058-SC has
demonstrated an effect on building bone. The Company also has a
next-generation transdermal patch, BA058-TD, being developed as a short
wear-time delivery vehicle intended to improve patient compliance with
convenience and ease of use, as well as a product in development to treat
symptoms associated with menopause.

About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to
develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery
technology including microneedles. 3M offers a full range of feasibility,
development and manufacturing capabilities combined with regulatory guidance
to help bring products to market. In-house resources, including toxicology,
regulatory expertise, quality assurance, operations, and marketed product
support, are available for each step of the development and commercialization
process. This depth of resources is one reason why more than 50 percent of all
metered-dose inhalers worldwide and 60 percent of all transdermal systems in
the United States utilize 3M drug delivery technology. For more information,
please visit www.3M.com/dds or call 1-800-643-8086.

About 3M

3M captures the spark of new ideas and transforms them into thousands of
ingenious products. Our culture of creative collaboration inspires a
never-ending stream of powerful technologies that make life better. 3M is the
innovation company that never stops inventing. With $30 billion in sales, 3M
employs about 84,000 people worldwide and has operations in more than 65
countries. For more information, visit www.3M.com or follow @3MNews on
Twitter.

3M is a trademark of 3M Company.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20121220006422/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50515205&lang=en

Contact:

LaVoie Group
Radius
David Connolly, 617-374-8800
dconnolly@lavoiegroup.com
or
3M Drug Delivery Systems
Arina A. Paoli, 651-733-5615
aapaoli@mmm.com
 
Press spacebar to pause and continue. Press esc to stop.